Abstract:Tuberculosis (TB) is a life-threatening disease resulting in an estimated 10 million new infections and 1.8 million deaths annually, primarily in underdeveloped countries. The economic burden of TB has been estimated as approximately 12 billion USD annually in direct and indirect costs. Additionally, multi-drug-resistant (MDR) and extreme-drug-resistant (XTR) TB strains resulting in about 250 000 deaths annually are now widespread, increasing pressure on the identification of new anti-TB agents that operate by a novel mechanism of action. Chrysomycin A is a rare C-aryl glycoside first discovered over 60 years ago. In a recent high-throughput screen, we found that chrysomycin A has potent anti-TB activity, with minimum inhibitory concentration (MIC) = 0.4 pg/mL against MDR-TB strains. However, chrysomycin A is obtained in low yields from fermentation of Streptomyces, and the mechanism of action of this compound is unknown. To facilitate the mechanism of action and preclinical studies of chrysomycin A, we developed a 10-step, scalable synthesis of the isolate and its two natural congeners polycarcin V and gilvocarcin V. The synthetic sequence was enabled by the implementation of two sequential C-H functionalization steps as well as a late-stage C-glycosylation. In addition, >10 g of the advanced synthetic intermediate has been prepared, which greatly facilitated the synthesis of 33 new analogues to date. The structure-activity relationship was subsequently delineated, leading to the identification of derivatives with superior potency against MDR-TB (MIC = 0.08 mu g/mL). The more potent derivatives contained a modified carbohydrate residue which suggests that further optimization is additionally possible. The chemistry we report here establishes a platform for the development of a novel class of anti-TB agents active against drug-resistant pathogens.

Concise synthesis of the C15–C25 fragment of Thuggacins A-C

Efforts toward the Total Synthesis of Thuggacin A

Stereoselective synthesis of the C1–C12 fragment of the thuggacins

Practical Synthesis of Macrobicyclic Thiolincosamines

Total synthesis of tubulysin U and its C-4 epimer.

Synthesis of the C1–C12 Acid Fragment of Amphidinolide T Marine Macrolides Via SmI2-mediated Enantioselective Reductive Coupling of Aldehydes with a Chiral Crotonate

Synthesis of C13-C25 fragment of 24-demethylbafilomycin C1 via diastereoselective aldol reactions of a ketone boron enolate as the key step

Scalable total synthesis of a mycobactin T analogue utilizing a novel synthetic and protection strategy

A Concise Total Synthesis of Amphidinin B

Divergent Total Syntheses of (+)‐vulgarisins A–E

A Facile Synthesis and M. Tuberculosis Leucyl-tRNA Synthetase Inhi-bitory Activity of Novel 3-Arylvinylquinoxaline-2-carboxylic Acids

An Enantioselective Total Synthesis of Tubulysin V

Synthesis of the I-K Fused Polyether Array of CTX3C and Related Ciguatoxins by Use of a Gold-Catalyzed Cyclization Reaction

A Facile Route To The Total Synthesis Of Gigantetrocin A

Chrysomycin A Derivatives for the Treatment of Multi-Drug-Resistant Tuberculosis.

Total Synthesis of (–)-Cordycicadin D and 3,4-trans-Cordycicadins A and B: Entry to the 3,4-trans-Fused Cordycicadin Framework

Snapshots of Catalysis: Structure of Covalently Bound Substrate Trapped in Mycobacterium Tuberculosis Thiazole Synthase (Thig).

Total Synthesis of Gigantetrocin A

Quinoline derivatives as potential anti-tubercular agents: Synthesis, molecular docking and mechanism of action

Total Synthesis of the Guangnanmycin A Alcohol

Total Synthesis and Structural Reassignment of the Antitubercular Natural Product Evybactin